PMV Pharmaceuticals Inc. (NASDAQ: PMVP) is making moves in the fight against ovarian cancer. On Monday, the company shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for the disease. The results are promising enough that the company is gearing up to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval.
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
MarketDash
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
Get PMV Pharmaceuticals Alerts
Weekly insights + SMS alerts
Efficacy Highlights
The interim data, collected up to May 14, 2026, focuses on patients with platinum-resistant or refractory ovarian cancer who carry the TP53 Y220C mutation. Among the 76 patients evaluated, the drug achieved a 46% overall response rate (ORR), including four confirmed complete responses and 29 confirmed partial responses.
Rezatapopt also demonstrated a median duration of response of 10.0 months, suggesting the drug's effects are not just quick but lasting. The safety profile looks favorable too, with mostly Grade 1 and 2 treatment-related adverse events and a low 5% discontinuation rate tied to those events.
Regulatory Path
The company plans to present a comprehensive update on all PYNNACLE Phase 2 cohorts at an upcoming medical conference in the fourth quarter of 2026. Following a recent FDA meeting, PMV Pharmaceuticals received feedback supporting its strategy to seek accelerated approval for rezatapopt. The company intends to submit the NDA in the first quarter of 2027.
Funding The Future
In related news, PMV Pharmaceuticals priced a public offering expected to generate approximately $50.8 million in gross proceeds. The offering includes shares of common stock, pre-funded warrants, and accompanying warrants, with a combined public offering price of $1.21 per share and warrant combination. This financial move supports the company's ongoing research and anticipated regulatory submissions.
PMVP Price Action: PMV Pharmaceuticals shares were down 10.74% at $1.08 during premarket trading on Tuesday, according to market data.
More News
AfD's Historic Win and $97 Oil Shake European Markets as Wall Street Takes a Day Off
Iran and Oman Close to Deal on Safe Shipping Lanes in Strait of Hormuz
Bessent Sees Oil at $40-$50 Post-Iran War, Schiff Says Don't Believe It
Nvidia's Hugging Face Deal Is About More Than Just Chips
Germany's Far-Right Election Win: A Headache for Investors?
Elon Musk's Boring Company Has an Unusual Requirement for Its New Funding Round
Oracle's Biggest AI Risk May No Longer Be Spending
Why Rising Bond Yields May Be Just 'Noise' For Stocks, Jordi Visser Says
Get PMV Pharmaceuticals Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all newsAfD's Historic Win and $97 Oil Shake European Markets as Wall Street Takes a Day Off
By MarketDash
September 7, 2026
Iran and Oman Close to Deal on Safe Shipping Lanes in Strait of Hormuz
By MarketDash
September 7, 2026
Bessent Sees Oil at $40-$50 Post-Iran War, Schiff Says Don't Believe It
By MarketDash
September 7, 2026
Nvidia's Hugging Face Deal Is About More Than Just Chips
By MarketDash
September 7, 2026
Germany's Far-Right Election Win: A Headache for Investors?
By MarketDash
September 7, 2026
Elon Musk's Boring Company Has an Unusual Requirement for Its New Funding Round
By MarketDash
September 7, 2026
Oracle's Biggest AI Risk May No Longer Be Spending
By MarketDash
September 7, 2026
Why Rising Bond Yields May Be Just 'Noise' For Stocks, Jordi Visser Says
By MarketDash
September 7, 2026